Pola Pharma Inc.

Nihon Nohyaku Co., Ltd.

Nobuo Kubota

Hirokazu Kobayashi

Yasushi Murakami

Azuma Nishio

Naoko Kobayashi

Takaaki Masuda

Eiko Kosugi

Akira Nozawa

Toyohiko Miki

Kahori Fujii

Tsuyoshi Shimamura

Susumu Tomiyama

Saori Nagasaka

Provided is a product exhibiting good bubbles even from a screen foamer composition using a non-ionic surfactant. This foam contains a non-ionic surfactant and is composed of an air layer and a bubble shell encapsulating the air layer. The bubble shell has a high light transmission region which is optically transparent and a low light transmission region which is less optically transparent than the highlight transmission region, both regions being disposed so as to spread across a surface of the bubble shell in such a manner as to form an identifiable boundary therebetween; and when the foam is allowed to stand at 25&#xb0; C., an area of the low light transmission region occupying the surface area of the bubble shell expands over time, and thus the entire surface of the bubble shell becomes occupied by the low light transmission region.

Foam, screen foamer composition, and evaluation method for same

In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof in an amount of 5% by mass or more, comprised is/are acetone, a polyoxyethylene alkyl (having 8 to 30 carbon atoms) ether, and/or a polyoxyethylene alkenyl (having 8 to 30 carbon atoms) ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrrolidone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60&#xb0; C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20&#xb0; C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5&#xb0; C. for 2 weeks after manufacture.

Antimycotic pharmaceutical composition

The invention can produce an infected nail of an animal and an infected animal model in which the nail plate and nail bed of the nail are sufficiently infected with a superficial fungus which were difficult to be produced in the past, and provides an evaluation method useful for development of a therapeutic agent for intractable infectious diseases such as tinea unguium using the nail and the infected animal model. For producing the infected nail of an animal and the infected animal model infected with a superficial fungus, an immunosuppressive component is administered to an animal in advance to decrease immunocompetence, and then, a superficial fungus is inoculated into the animal, whereby the infected nail of an animal and the infected animal model reflecting clinical manifestation in which the nail plate and nail bed of the nail are sufficiently infected with the superficial fungus can be produced with good reproducibility in a short period of time.

Infected nail of animal infected with fungus

In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof, comprised are a higher alcohol which is in a liquid state at 1 atm and 25&#xb0; C. and/or a diester of a dibasic acid, provided that a diester carbonate is excluded, and a polyoxyethylene alkyl ether and/or a polyoxyethylene alkenyl ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrroridone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60 degrees C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20&#xb0; C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5&#xb0; C. for 2 weeks after manufacture.

An object is to provide a medicament preparation which is excellent in the solubilization stability in relation to a compound represented by the general formula (1) during the storage in a low temperature region and a high temperature region. The present invention resides in a pharmaceutical composition comprising 1) the compound represented by the general formula (1) and/or a salt thereof and 2) a polyhydric alcohol derivative. General formula (1) (In the formula, R, Rindependently represent hydrogen atom or halogen atom respectively, and at least one of R, Ris halogen atom.) 

A pharmaceutical composition which comprises 1) a compound represented by the following general formula (1) and/or a salt thereof; and 2) a ketone such as methyl ethyl ketone. Preferably, the compound represented by the following general formula (1) is luliconazole, where R&#x2550;R=a chlorine atom: where Rand Reach independently represents a hydrogen atom or a halogen atom, and at least one of Rand Rrepresents a halogen atom. The present invention provides a preparation excellent in solubilization stability for a compound represented by the general formula (1) and/or a salt thereof in low-temperature or high-temperature storage. 

To provide a pharmaceutical composition which can enhance the storage stability of 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole without impairing the effect of the compound. The pharmaceutical composition includes 1-(1-hydroxymethyl-2,3-dihydroxypropyloxymethyl)-2-nitroimidazole, which is represented by formula (1): and a compound having chelating ability.

Pharmaceutical composition

Provided is a pharmaceutical composition for external use, including: (i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and (ii) &#x3b1;-hydroxycarboxylic acid and/or a salt thereof. 

Pharmaceutical composition for external use

To provide a pharmaceutical composition containing a 2-nitroimidazole derivative, which has high solubility in an aqueous carrier and high stability. The pharmaceutical composition is characterized by containing 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole and creatinine, and containing creatinine of 0.001 to 1 part by mass with respect to 1 part by mass of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole.

A Cancer radiotherapeutic method using 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole (compound (i), and creatinine in an amount of 0.001 to part by mass with respect to 1 part by mass of compound (1); and irradiation.

Growing community of inventors

Yokohama, Japan

Nobuo Kubota